Cipla doubles up Remdesivir production as shortage continues

Cipla has doubled production of COVID-19 medication Remdesivir to help meet “unprecedented demand” . The recent spike in COVID-19 cases and hospitalizations has lead to an increase in demand for the drug as it is used to treat patients with severe complications.

"We have scaled up the production of Remdesivir by 2x from the last wave of the pandemic. Given the unprecedented demand for the drug, we have now further ramped up our capacities through our network, to service the demand," Cipla said in a statement

The shortage in the market has been severe, in a letter to the Drug Controller General of India (DCGI), LocalCircles pointed out that over the last week, many posts and comments received from various cities of India have quoted the drug selling for as high as Rs 50,000 over 10 times of the retail price of the drug.